Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 69Leukemia, Myeloid, Acute 32Carcinoma, Renal Cell 27Neoplasm Metastasis 17Breast Neoplasms 16Leukemia 15Neuroblastoma 14Kidney Neoplasms 14Lymphoma, Non-Hodgkin 12Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Myelodysplastic Syndromes 10Recurrence 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma 7Congenital Abnormalities 7Colorectal Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Skin Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Head and Neck Neoplasms 5Fallopian Tube Neoplasms 5Carcinoma, Hepatocellular 5Rectal Neoplasms 4Mesothelioma, Malignant 4Lung Neoplasms 4

Interventions

Cyclophosphamide 10fludarabine 7Rituximab 6Bendamustine Hydrochloride 5venetoclax 4obinutuzumab 4Lenalidomide 4ofatumumab 3ibrutinib 3fludarabine phosphate 3acalabrutinib 3Vincristine 3Immunotherapy, Adoptive 3pirtobrutinib 2Bortezomib 2Alemtuzumab 2zanubrutinib 1thymoglobulin 1tenofovir alafenamide 1ricolinostat 1pembrolizumab 1pegaspargase 1nelarabine 1idelalisib 1blinatumomab 1Whole-Body Irradiation 1Prednisolone 1Pentostatin 1Panobinostat 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, B-Cell × Interleukin-2 × Clear all
NCT03098355 2024-03-18

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Zhujiang Hospital

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡